Lead: On 2 April 2026 the US Centers for Disease Control and Prevention (CDC) announced a temporary suspension of more than two dozen diagnostic tests—affecting assays for rabies, human herpesviruses and other pathogens—after an internal review and amid staffing shortfalls. The agency said the pause is part of a routine evaluation begun in late 2024 and that many tests may resume in the coming weeks. State and local health departments that rely on CDC support are being steered toward alternate laboratories while the agency reassesses capacity. The agency attributed the service gap to a mix of layoffs, hiring freezes and departures that have reduced experienced lab staff.
Key takeaways
- CDC released a list on 2 April 2026 showing more than two dozen types of testing are currently unavailable to state and local partners.
- Suspended assays include tests for rabies, human herpesviruses (including Epstein-Barr), and varicella zoster virus, along with rarer parasites and viruses.
- The agency says the pause stems from a routine program review begun in late 2024 and will coordinate alternative testing options where possible.
- Workforce reductions—driven by layoffs, retirements, resignations and expired temporary roles—have cut overall CDC staffing by an estimated 20–25%, according to Associated Press estimates.
- By July, reporting from the New York Times indicates the rabies response team will have just one clinical expert and the poxvirus team none, constraining direct CDC guidance.
- Internal reorganizations and political interventions in 2025–2026, including changes at HHS and advisory committees, have compounded operational disruption across some CDC programs.
Background
The CDC has long served as a national reference lab, offering specialized testing that many state and local public health laboratories cannot perform. These reference services supplement local capacity for rare pathogens and provide confirmatory testing for high-consequence infections. In late 2024 the agency initiated a review of its testing portfolio intended to standardize assays and ensure quality control across labs.
Over the past year the CDC experienced a series of workforce changes: layoffs, hiring pauses, natural retirements, resignations and the end of temporary contracts. News reports and employee groups say those shifts have been substantial enough to remove experienced scientists from core units, reducing surge capacity and bench-level expertise. The loss of institutional know‑how has contributed to decisions to pause some assays while the programs are evaluated and staffing gaps addressed.
Main event
On 2 April 2026 the CDC published a list identifying more than two dozen tests that are temporarily unavailable. The list ranges from relatively common viral assays—for which commercial testing exists—to specialized diagnostics for parasites and rare viruses. The agency characterized the suspension as temporary and tied to an ongoing internal evaluation of assay performance and laboratory readiness.
A CDC spokesperson told reporters the agency is communicating with state and local health departments and can help arrange testing through alternate public-health or commercial laboratories when needed. Agency officials said they expect some services to be reinstated within weeks but gave no firm timeline for full restoration of all paused assays.
Reporting from other outlets has tied the service pause to recent staffing losses. By July, according to the New York Times, the CDC rabies team will have only one clinician able to provide guidance to states; the poxvirus unit will reportedly have no clinicians in place. Employee groups—including the National Public Health Coalition—have said divisions such as malaria have been reduced even more drastically.
Analysis & implications
The immediate risk is operational: state and local public health labs that lack in-house capacity may face longer turnaround times or must depend on commercial laboratories, which can increase costs and complicate public-health surveillance. For diseases like rabies, timely confirmatory testing can influence management of exposed individuals and animal control measures; constrained CDC capacity could delay expert consultation.
For routine but high-volume pathogens (Epstein-Barr, varicella zoster), clinical care is rarely affected because commercial tests are widely available. The greater concern is for rare pathogens and specialized assays where commercial options are limited and CDC reference testing has been a critical safety net for outbreak detection and for confirmatory diagnosis in complex cases.
The workforce reductions have broader system implications. A 20–25% decline in staffing (Associated Press estimate) reduces bench capacity, mentorship and surge readiness. Losses concentrated in small, specialized teams—poxvirus, rabies, malaria—risk leaving gaps that are not quickly fixed by hiring, given the time required to recruit and acculturate experienced laboratorians.
Politically, recent interventions at HHS and the disruption to the advisory committee on immunization practices create uncertainty about longer-term priorities and governance at federal public-health institutions. That uncertainty may affect recruiting, retention and the willingness of state partners to rely on federal laboratories during crises.
| Unit/Measure | Reported change |
|---|---|
| Total CDC staffing | Estimated −20% to −25% (Associated Press) |
| Poxvirus unit | Lost roughly half its staff (National Public Health Coalition) |
| Rabies unit | Lost roughly half its staff; by July will have 1 clinical expert (New York Times) |
| Malaria division | Cut more severely than other units (National Public Health Coalition) |
The table synthesizes published estimates from news organizations and employee groups. While percentage ranges and unit impacts vary by source, the pattern across reports shows concentratied reductions in small specialty teams and a substantial overall staffing decline. Reduced headcount can have outsized operational effects when losses fall on teams that manage rare but high-consequence pathogens.
Reactions & quotes
CDC officials emphasized quality control and temporary measures, saying the agency will work with partners to find alternative testing while internal reviews proceed. Public-health leaders at state health departments voiced concern about short-term logistics and longer-term capacity.
“Several infectious disease tests are temporarily paused as CDC evaluates these assays as part of our routine review to uphold high-quality laboratory testing,”
CDC spokesperson (paraphrased)
The CDC framed the pause as a quality-and-safety step and said it expects some tests to return within weeks. State officials say they have been notified and are exploring commercial or academic lab options to fill gaps while the agency reassesses testing programs.
“We are coordinating with CDC to identify alternative laboratories, but shorter-term delays are possible for certain specialized tests,”
State public health official (paraphrased)
Unconfirmed
- Exact timelines for when each paused assay will be reinstated remain unspecified; CDC has said some tests may return in “the coming weeks,” but no firm dates were provided.
- Precise headcount figures for each unit vary by source; some reports give approximate percentages rather than exact employee counts.
- Links between recent political decisions and specific testing pauses are reported by observers but lack direct, publicly available internal documentation tying individual program suspensions to those decisions.
Bottom line
The CDC pause of more than two dozen diagnostic tests is presented by the agency as a temporary, quality-driven measure, but it comes at a time of demonstrable staffing shortages that are already constraining subject-matter teams. For many routine infections commercial testing will bridge the gap; for rare pathogens, the interruption reduces a critical safety net for state and local public-health systems.
In the near term, public-health partners should inventory alternate laboratory pathways, prioritize tests by public-health impact, and document clinical and surveillance delays. Over the medium term, restoring capacity will require targeted hiring, retention measures for specialist staff, and transparent timelines from federal leadership about how and when paused services will return.
Sources
- The Guardian — news report summarizing CDC list and interviews (media).
- Centers for Disease Control and Prevention (CDC) — agency statements and laboratory program information (official source).
- The New York Times — reporting on unit staffing and clinical expertise projections (media).
- Associated Press — estimates of overall staffing declines (news agency).
- National Public Health Coalition — employee group commentary on division cuts (advocacy/former-employee group).